Skip to main content
. 2022 Jun 30;20:3511–3521. doi: 10.1016/j.csbj.2022.06.058

Fig. 3.

Fig. 3

Profiles for multi-omics landmark signatures between high-risk subgroup and low-risk subgroup. (A) POLR3A CNV (Wilcoxon test, P-value < 2.2e-16). (B) MSN gene expression (Wilcoxon test, P-value < 2.2e-16). (C) GPX4 methylation (Wilcoxon test, P-value < 2.2e-16). (D) ANXA1 protein expression (Wilcoxon test, P-value = 9.3e-07). (E) MIR155 miRNA expression (Wilcoxon test, P-value < 2.2e-16).(F) IDH1,chr2:209113112–209113112,+,Missense_Mutation,SNP,CC > CT (Chi-Square test, P-value < 2.2e-16).